Invasive breast cancers yielding ‘HER2 negative’ results (IHC 0, 1+, or 2+/ISH non-amplified) are more specifically considered ‘HER2 negative for protein overexpression/genetic amplification’, as non-overexpressed levels of the HER2 protein may be present in these cases. This evidence concerns the gene ERBB2 and breast carcinoma.